| |
Generative AI has the potential to accelerate innovations across the value chain, from R&D to commercialization. Watch this webinar series to learn why nine out of the top 10 biopharma organizations use AWS for machine learning and analytics. Watch now.
|
|
Today’s Big NewsAug 31, 2023 |
|
Government Biotechnology Innovation Summit Convenes September 27-28 in National Harbor, MD. Hear from government leaders at the forefront on how biotechnology is transforming the economic, agricultural, healthcare and security landscape of the U.S. Learn more.
|
|
| By Zoey Becker Bill Sibold, who took over the company's specialty care unit in 2017 just after Dupixent's first approval, is leaving Sanofi effective immediately. The company further shook up its leadership by appointing a new R&D head, a chief digital officer and adding an entirely new position. |
|
|
|
By Nick Paul Taylor Bristol Myers Squibb has reported full phase 1 data on one of its successors to Revlimid and Pomalyst. An outside expert called the multiple myeloma survival data “modest,” but the potential for the therapy, mezigdomide, to find a place in combination therapies is spurring hopes heading into phase 3 readouts. |
By Kevin Dunleavy It was a year ago this month that President Joe Biden signed the Inflation Reduction Act. While the landmark bill introduces several pricing measures, Democrats on Capitol Hill are still pursuing ways to rein in the pharma industry. They are pressing insulin manufacturers on their plans to cut prices. They also are asking the FDA to adjust its management of the patent system to bolster competition. |
By Andrea Park In recent years, as ventilators have become increasingly crucial amid the COVID-19 pandemic, malfunctioning devices have been a constant burr in the FDA’s side. |
|
Wednesday, September 6, 2023 | 2:00 PM ET / 11:00 AM PT Attendees will learn about the latest tools for interacting with medical images, how to guide readers through labeling workflows, and streamlining adjudication and data standardization. Discussions will include real-world use cases of how pharma companies are enhancing AI development by optimizing reader workflows. Register now.
|
|
By Kevin Dunleavy Seven weeks after saying it would allow generic competition for drug-resistant tuberculosis (TB) treatment Sirturo (bedaquiline) in low- and middle-income countries (LMICs), Johnson & Johnson has slashed its own drug's price by 55% to $130 for a six-month course. |
By James Waldron Sage Therapeutics will jettison 40% of its workforce as the company navigates a future for its Biogen-partnered drug after the therapy was rejected as a treatment for major depressive disorder. |
By Conor Hale After watching its share price evaporate alongside sharply declining interest in COVID-19 diagnostics, the testmaker Cue Health is now facing public appeals from investors to appoint new representatives to its board. |
By Zoey Becker After 16 years on the market, Takeda's blockbuster ADHD med Vyvanse has finally reached its patent cliff. And the FDA's approval of several generics comes amid a U.S. shortage of the drug. |
By Max Bayer ADC Therapeutics is stepping away from a 2019 licensing pact with Adagene following a refocused clinical development plan. Adagene received an undisclosed upfront payment and research reimbursement when the deal was first signed. |
By Andrea Park In the wake of earning FDA clearance for its insulin pump and automated dosing software—creating what’s known as a hybrid closed-loop system for diabetes management—Beta Bionics is raking in the dough. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
---|
|
|
WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| |
|